Nephrocare Health Services Limited Q1 FY27 results deck summary

Results deck of 11 Aug 2026, summarised by AI from the filing.

No forward guidance was provided in the presentation.

Key takeaways

1. Guidance No forward guidance was provided in the presentation.
2. Network expansion Added 7 clinics in Philippines (total 51), expanded Uzbekistan footprint, commenced home dialysis in Saudi Arabia.
3. Growth drivers Volume growth (treatments +13.3%, guests +13.0%) and 9.2% YoY RPT improvement to ₹2,733 drove revenue.

Original filing on BSE

Nephrocare Health Services Limited Q1 FY27 results

As filed: Revenue ₹282 cr, EBITDA ₹63.9 cr, PAT ₹32.0 cr, EBITDA margin 22.7%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹282 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹266 cr, EBITDA ₹53.8 cr, PAT ₹30.4 cr, EBITDA margin 20.2%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹266 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.3% in 30 days (Nifty 500: +3.0%).
• Q3 FY26: Revenue ₹260 cr, EBITDA ₹60.9 cr, PAT ₹32.2 cr, EBITDA margin 23.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹260 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +4.5% in 30 days (Nifty 500: −7.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Nephrocare Health Services Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (12 Aug 2026), Results deck (11 Aug 2026), Results press release (11 Aug 2026)
• Q4 FY26: Earnings call (20 May 2026), Results deck (19 May 2026), Results press release (19 May 2026)
• Q3 FY26: Earnings call (11 Feb 2026), Results deck (10 Feb 2026), Results press release (10 Feb 2026)